Biothera Launches Clinical Trial in KRAS-Mutated Colorectal Cancer Patients

June 10, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

EAGAN, Minn.--(BUSINESS WIRE)--Biothera has initiated a Phase II clinical trial in stage IV KRAS-mutated colorectal cancer patients with its investigational drug Imprime PGG® in combination with Erbitux® (cetuximab), the company announced today.

Twitter
LinkedIn
Facebook
Email
Print

Clinical research Phase 2